Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Schmidt

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Annals of Hematology|June 28, 2018
Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency-a case report and comprehensive review of the literatureAlexander Simonis, Michaela Fux, Gayathri Nair, et al.
British Journal of Haematology|May 6, 2021
A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validationGuido Willekens, Jan-Dirk Studt, Adriana Mendez, et al.
Cancer Epidemiology|January 29, 2019
Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registriesSonia Benzarti, Michael Daskalakis, Anita Feller, et al.
Leukemia & Lymphoma|August 22, 2018
Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantationCéline M Mürner, Frank Stenner-Liewen, Burkhardt Seifert, et al.
Cancer Epidemiology|January 6, 2017
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012Nicolas Bonadies, Anita Feller, Alicia Rovo, et al.
Frontiers in Cardiovascular Medicine|September 27, 2021
Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban MeasurementsTamana Meihandoest, Jan-Dirk Studt, Adriana Mendez, et al.
Diagnostics (Basel, Switzerland)|June 28, 2023
Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban CalibratorAnnika Burger, Jan-Dirk Studt, Adriana Mendez, et al.
Swiss Medical Weekly|April 4, 2019
Updated recommendations for diagnosis and treatment of plasma cell myeloma in SwitzerlandPanagiotis Samaras, Mario Bargetzi, Daniel C Betticher, et al.
Frontiers in Cardiovascular Medicine|April 4, 2022
Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional StudyTamana Meihandoest, Jan-Dirk Studt, Adriana Mendez, et al.
Journal of Clinical Apheresis|March 23, 2016
Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patientsJulia-Tatjana Maul, Frank Stenner-Liewen, Burkhardt Seifert, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Annals of Hematology|June 28, 2018
Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency-a case report and comprehensive review of the literatureAlexander Simonis, Michaela Fux, Gayathri Nair, et al.
British Journal of Haematology|May 6, 2021
A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validationGuido Willekens, Jan-Dirk Studt, Adriana Mendez, et al.
Cancer Epidemiology|January 29, 2019
Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registriesSonia Benzarti, Michael Daskalakis, Anita Feller, et al.
Leukemia & Lymphoma|August 22, 2018
Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantationCéline M Mürner, Frank Stenner-Liewen, Burkhardt Seifert, et al.
Cancer Epidemiology|January 6, 2017
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012Nicolas Bonadies, Anita Feller, Alicia Rovo, et al.
Frontiers in Cardiovascular Medicine|September 27, 2021
Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban MeasurementsTamana Meihandoest, Jan-Dirk Studt, Adriana Mendez, et al.
Diagnostics (Basel, Switzerland)|June 28, 2023
Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban CalibratorAnnika Burger, Jan-Dirk Studt, Adriana Mendez, et al.
Swiss Medical Weekly|April 4, 2019
Updated recommendations for diagnosis and treatment of plasma cell myeloma in SwitzerlandPanagiotis Samaras, Mario Bargetzi, Daniel C Betticher, et al.
Frontiers in Cardiovascular Medicine|April 4, 2022
Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional StudyTamana Meihandoest, Jan-Dirk Studt, Adriana Mendez, et al.
Journal of Clinical Apheresis|March 23, 2016
Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patientsJulia-Tatjana Maul, Frank Stenner-Liewen, Burkhardt Seifert, et al.
Pageof 5